Related Experiment Videos
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
J A Johnson1, L Gong, M Whirl-Carrillo
1Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA. Johnson@cop.ufl.edu
Clinical Pharmacology and Therapeutics
|September 9, 2011
Summary
Genetic variants in CYP2C9 and VKORC1 impact warfarin dosing. This guide helps clinicians use genotype data to personalize warfarin therapy for better anticoagulation.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
Background:
- Warfarin is a critical anticoagulant with significant dose variability.
- Cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) genetic variants influence warfarin metabolism and efficacy.
- Nongenetic factors also contribute to interpatient warfarin dose differences.
Purpose of the Study:
- To provide guidance on interpreting CYP2C9 and VKORC1 genotype data.
- To assist clinicians in estimating optimal warfarin dosage for therapeutic anticoagulation (INR 2-3).
- To facilitate the clinical application of pharmacogenetic information for warfarin therapy.
Main Methods:
- Review of existing scientific literature on CYP2C9 and VKORC1 gene-drug interactions.
- Analysis of data from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
- Development of evidence-based guidelines for warfarin dosing based on genotype.
Main Results:
- Common genetic variants in CYP2C9 and VKORC1 explain a substantial portion of warfarin dose variability.
- Genotype information can significantly improve the accuracy of initial warfarin dose selection.
- Personalized dosing strategies based on pharmacogenetics lead to more predictable anticoagulation.
Conclusions:
- CYP2C9 and VKORC1 genotyping is valuable for optimizing warfarin therapy.
- Clinical implementation of pharmacogenetic data enhances warfarin safety and effectiveness.
- Guidelines from CPIC support the use of genetic information in warfarin prescribing.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...